{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:44:48Z","timestamp":1767109488413,"version":"3.40.5"},"reference-count":178,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/14728214.2020.1810663","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T10:49:31Z","timestamp":1597574971000},"page":"337-351","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Emerging therapeutics for the management of COVID 19"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-7686","authenticated-orcid":false,"given":"Sujit Kumar","family":"Debnath","sequence":"first","affiliation":[{"name":"Nanobios Lab, Department of Biosciences and Bioengineering, IIT Bombay, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-5139","authenticated-orcid":false,"given":"Rohit","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Nanobios Lab, Department of Biosciences and Bioengineering, IIT Bombay, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-5762","authenticated-orcid":false,"given":"Abdelwahab","family":"Omri","sequence":"additional","affiliation":[{"name":"The Novel Drug and Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"cit0001","unstructured":"ET online. ET explains: everything you need to know about the novel coronavirus. Indian Times. 2020. p. 1."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.onehlt.2020.100128"},{"key":"cit0003","first-page":"2781","volume":"24","author":"Ceccarelli M","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"cit0004","unstructured":"Sauer LM. What is coronavirus? Johns Hopkins Med; 2020 [cited 2020 Apr 10]. Available from: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/coronavirus. p. 1."},{"key":"cit0005","unstructured":"Hazelton A. COVID-19: top four science stories of the week. World Econ Forum; 2020 [cited 2020 May 6]. Available from: https:\/\/www.weforum.org\/agenda\/2020\/04\/covid-19-latest-scientific-developments\/. p. 1."},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8497"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2020.1727993"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-020-03263-6"},{"key":"cit0009","unstructured":"Zhang Y, Zhang C, Zheng W. More evidence suggests pangolins may have passed Coronavirus from bats to humans. Sci Alert; 2020 [cited 2020 Apr 17]. Available from: https:\/\/www.sciencealert.com\/more-evidence-suggests-pangolins-may-have-passed-coronavirus-from-bats-to-humans. p. 1."},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3201\/eid1212.060401"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/path.1560"},{"key":"cit0012","first-page":"1","author":"Dawood FS","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"cit0013","unstructured":"Worldometer. Coronavirus update (Live): 1,925,224 cases and 119,702 deaths from COVID-19 virus pandemic. Worldometers; 2020 [cited 2020 Apr 14]. Available from: https:\/\/www.worldometers.info\/coronavirus\/? p. 1."},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00483-20"},{"key":"cit0015","unstructured":"Duddu P. Coronavirus outbreak: top coronavirus drugs and vaccines in development. Clin Trials Arena; 2020 [cited 2020 Apr 12]. Available from: https:\/\/www.clinicaltrialsarena.com\/analysis\/coronavirus-mers-cov-drugs\/"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1093\/EHJCVP\/PVAA041"},{"key":"cit0018","unstructured":"Thomas K, Sheikh K. Small chloroquine study halted over risk of fatal heart complications. New York Times. 2020. p. 1."},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-019-0132-8"},{"key":"cit0020","first-page":"1179","volume":"395","author":"Jaffe S","year":"2020","journal-title":"World Rep"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(10)80012-5"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa396"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019"},{"key":"cit0024","first-page":"1","author":"Le PM","year":"2020","journal-title":"New Sci"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040758"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.16.20037135"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1857"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1834"},{"key":"cit0029","unstructured":"Hydroxychloroquine or chloroquine for COVID-19: drug safety communication- FDA cautions against use outside of the hospital setting or a clinical trial due to risk of heart rhythm problems | FDA; 2020 [cited 2020 Jun 15]. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016638"},{"key":"cit0032","unstructured":"FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine; 2020 [cited 2020 Jun 17]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. p. 1."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30141-9"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4940"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"cit0036","unstructured":"Varghese J Convalescent plasma therapy for COVID-19. The Hindu. 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.thehindu.com\/sci-tech\/health\/convalescent-plasma-therapy-for-covid-19\/article31371149.ece. p. 1."},{"key":"cit0037","unstructured":"FDA. Recommendations for investigational COVID-19 convalescent plasma. Food Drug Adm; 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma. p. 1."},{"key":"cit0038","unstructured":"ICMR gets nod for clinical trial of convalescent plasma for COVID-19 treatment. The Hindu. 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.thehindu.com\/sci-tech\/health\/icmr-gets-nod-for-clinical-trial-of-convalescent-plasma-for-covid-19-treatment\/article31372977.ece. p. 1."},{"journal-title":"J Infect Dis","year":"2020","author":"Zeng Q-L","key":"cit0039"},{"key":"cit0040","unstructured":"Gallagher GM. Is there any reason to use corticosteroids in coronavirus treatment? Infect Dis Today; 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.contagionlive.com\/news\/is-there-any-reason-to-use-corticosteroids-in-coronavirus-treatment. p. 1."},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.07.006"},{"key":"cit0043","unstructured":"Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Univ Oxford; 2020 [cited 2020 Jun 18]. Available from: http:\/\/www.ox.ac.uk\/news\/2020-06-16-low-cost-dexamethasone-reduces-death-one-third-hospitalised-patients-severe"},{"key":"cit0044","first-page":"pvaa036","author":"Atallah B","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14817"},{"key":"cit0046","unstructured":"Velasco J. Heparin and Coronavirus. Bioiberica; 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.bioiberica.com\/en\/media\/blog\/science\/heparin-and-coronavirus. p. 1."},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1741327"},{"journal-title":"Eur Heart J","first-page":"2020;41:2122","author":"Wei X","key":"cit0048"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017529"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200"},{"key":"cit0051","first-page":"35:1073\u20131075","author":"Essig M","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2020.03.005"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104803"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(15)61444-9"},{"key":"cit0056","first-page":"1","author":"Virani SS","year":"2020","journal-title":"Am Coll Cardiol"},{"key":"cit0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.37080\/nmj.77","volume":"3","author":"Shrestha SK","year":"2020","journal-title":"Nepal Med J"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1093\/EHJCVP\/PVAA042"},{"key":"cit0059","first-page":"1","author":"Markus H","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"cit0060","unstructured":"Open label study to compare efficacy, safety and tolerability of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine combined with camostat mesylate and to \u201cno treatment\u201d in SARS CoV 2 virus - full Text View - ClinicalTrials.gov; 2020 [cited 2020 Jun 16]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04355052"},{"key":"cit0061","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/135965350601100803","volume":"11","author":"Amici C","year":"2006","journal-title":"Antivir Ther"},{"key":"cit0062","unstructured":"APHA. coronavirus watch: nSAIDs okay for COVID-19 patients. Am Pharm Assoc; 2020 [cited 2020 Apr 19]. Available from: https:\/\/www.pharmacist.com\/article\/apha-coronavirus-watch-nsaids-okay-covid-19-patients. p. 1."},{"key":"cit0063","unstructured":"FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. Food Drug Adm; 2020 [cited 2020 Apr 19]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19. p. 1."},{"key":"cit0064","unstructured":"Mezher M. EMA: no evidence NSAIDs unsafe with coronavirus amid confusion. Regul Focus; 2020 [cited 2020 Apr 19]. Available from: https:\/\/www.raps.org\/news-and-articles\/news-articles\/2020\/3\/ema-no-evidence-nsaids-unsafe-with-coronavirus-ami. p. 1."},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0221-9"},{"key":"cit0066","unstructured":"Hale C. FDA opens up Bellerophon\u2019s gas therapy for COVID-19, stock rockets. Fierce Biotech; 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.fiercebiotech.com\/medtech\/fda-expands-access-to-bellerophon-s-nitric-oxide-gas-for-covid-19-lung-symptoms. p. 1."},{"key":"cit0067","unstructured":"Duddu P. Coronavirus treatment: vaccines\/drugs in the pipeline for COVID-19. Clin Trials Arena; 2020 [cited 2020 Apr 7]. Available from: https:\/\/www.clinicaltrialsarena.com\/analysis\/coronavirus-mers-cov-drugs\/. p. 1."},{"key":"cit0068","unstructured":"Smith A Emergent biosolutions, eyeing two plasma therapies for Covid-19, wins fed\u2019s help. TheStreet; 2020 [cited 2020 Apr 13]. Available from: https:\/\/www.thestreet.com\/investing\/emergent-biosolutions-eyeing-two-plasma-therapies-for-covid-19-wins-feds-help. p. 1."},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1624482"},{"volume-title":"Features, evaluation and treatment coronavirus (COVID-19)","year":"2020","author":"Cascella M","key":"cit0070"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-110615-042301"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit393"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_115_20"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-7448-8_10"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwaa042"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S3285"},{"volume-title":"WHO model list of essential medicines 18th list (April 2013)","year":"2013","author":"WHO","key":"cit0078"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"#cr-split#-cit0080.1","unstructured":"Anesi GL. Coronavirus disease 2019 (COVID-19): critical care issues. UpToDate"},{"key":"#cr-split#-cit0080.2","unstructured":"2020 [cited 2020 Apr 18]. Available from: https:\/\/www.uptodate.com\/contents\/coronavirus-disease-2019-covid-19-critical-care-issues"},{"key":"cit0081","unstructured":"Ltd LBL. Lattice Biologics Ltd. announces initial recruitment of patients for a phase 1 clinical trial to access safety and efficacy of AmnioBoost for treatment of COVID-19. Biospace; 2020[cited 2020 Apr 12]. Available from: https:\/\/www.biospace.com\/article\/releases\/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19\/. p. 1."},{"key":"cit0082","unstructured":"Eastern Daylight Time. Lattice Biologics Ltd. announces initial recruitment of patients for a phase 1 clinical trial to access safety and efficacy of AmnioBoost for treatment of COVID-19. Bus Wire; 2020 [cited 2020 Apr 14]. Available from: https:\/\/www.businesswire.com\/news\/home\/20200317005218\/en\/Lattice-Biologics-Ltd.Announces-Initial-Recruitment-Patients. p. 1."},{"key":"cit0083","unstructured":"Speights K. Why BioCryst pharmaceuticals stock is jumping today. Motley Fool; 2020 [cited 2020 Apr 13]. Available from: https:\/\/www.fool.com\/investing\/2020\/01\/21\/why-biocryst-pharmaceuticals-stock-is-jumping-toda.aspx"},{"key":"cit0084","first-page":"1. [cited 2020","author":"Cahill J","year":"2020","journal-title":"Eur Pharm Rev"},{"key":"cit0085","unstructured":"Berger K. Favilavir: everything we know about the potential coronavirus treatment. Single Care; 2020 [cited 2020 Apr 14]. Available from: https:\/\/www.singlecare.com\/blog\/news\/favilavir-for-coronavirus\/. p. 1."},{"key":"cit0086","first-page":"1","author":"Ternyila D","year":"2020","journal-title":"Target Oncol"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0249-x"},{"key":"cit0088","unstructured":"Genentech. Actemra (tocilizumab) FDA approval history - Drugs.com. Food Drug Adm; 2010 [cited 2020 Apr 13]. Available from: https:\/\/www.drugs.com\/history\/actemra.html. p. 1."},{"key":"cit0089","unstructured":"Slater H FDA approves phase III clinical trial of Tocilizumab for COVID-19 pneumonia. MH Life Sci; 2020 [cited 2020 Apr 13]. Available from: https:\/\/www.cancernetwork.com\/news\/fda-approves-phase-iii-clinical-trial-tocilizumab-covid-19-pneumonia. p. 1."},{"key":"cit0090","unstructured":"Tarrytown NY. Regeneron and Sanofi announce FDA approval of Kevzara\u00ae (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients. Tarrytown (NY): Regeneron Pharmaceuticals Inc; 2017. p. 1."},{"key":"cit0091","unstructured":"US Department of Health & Human Services. HHS funds phase 2\/3 clinical trial for potential treatment for COVID-19. HHSGov; 2020 [cited 2020 Apr 13]. Available from: https:\/\/www.hhs.gov\/about\/news\/2020\/03\/21\/hhs-funds-phase-2-3-clinical-trial-for-potential-treatment-for-covid-19.html. p. 1."},{"key":"cit0092","unstructured":"Simonite T. AI uncovers a potential treatment for Covid-19 patients. WIRED. 2020 [cited 2020 Apr 18]. Available from: https:\/\/www.wired.com\/story\/ai-uncovers-potential-treatment-covid-19-patients\/. p. 1."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850127"},{"key":"cit0094","unstructured":"Food and Drug Administration. Synairgen doses first patient in COVID-19 trial. FDA News. 2020 [cited 2020 Apr 13]. Available from: https:\/\/www.fdanews.com\/articles\/196457-synairgen-doses-first-patient-in-covid-19-trial. p. 1."},{"key":"cit0095","first-page":"1","author":"Carrie A","year":"2020","journal-title":"New Sci"},{"key":"cit0096","unstructured":"Feuerstein A, Herper M. Gilead data suggests coronavirus patients are responding to treatment. Stat Newa; 2020[cited 2020 Apr 20]. Available from: https:\/\/www.statnews.com\/2020\/04\/16\/early-peek-at-data-on-gilead-coronavirus-drug-suggests-patients-are-responding-to-treatment\/. p. 1."},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.013056"},{"volume-title":"Gilead mulls repositioning failed Ebola drug in China virus","year":"2020","author":"Taylor NP","key":"cit0098"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"cit0100","first-page":"NEJMoa2007016","author":"Grein J","year":"2020","journal-title":"N Engl J Med"},{"key":"cit0101","unstructured":"Maffei D. Gilead announces results from phase 3 trial of investigational antiviral Remdesivir in patients with Severe COVID-19. Gilead Sci Inc; 2020 [cited 2020 May 5]. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/4\/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19. p. 1."},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00399-20"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.3390\/v11040326"},{"key":"cit0104","unstructured":"PTI. Coronavirus research exclusive: pharma drug candidates for coronavirus treatment. Thail Med News. 2020 [cited 2020 Apr 20]. Available from: https:\/\/www.thailandmedical.news\/news\/coronavirus-research-exclusive:pharma-drug-candidates-for-coronavirus-treatment. p. 1."},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2016.04.002"},{"key":"cit0106","unstructured":"Bluth J. BioCryst begins clinical trial with Galidesivir for treatment of patients with COVID-19. BioCryst Pharm; 2020 [cited 2020 Apr 20]. Available from: http:\/\/ir.biocryst.com\/news-releases\/news-release-details\/biocryst-begins-clinical-trial-galidesivir-treatment-patients. p. 1."},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.06.006"},{"key":"cit0108","unstructured":"PTI. Regeneron, Sanofi launch clinical trial of Kevzara as coronavirus treatment. Genet Eng Biotechnol News. 2020 [cited 2020 Apr 20]. Available from: https:\/\/www.genengnews.com\/news\/regeneron-sanofi-launch-clinical-trial-of-kevzara-as-coronavirus-treatment\/. p. 1."},{"key":"cit0109","unstructured":"Dunleavy BP China approves antiviral favilavir to treat coronavirus - UPI.com. Health News (Rochester). 2020 [cited 2020 Apr 7]. Available from: https:\/\/www.upi.com\/Health_News\/2020\/02\/17\/China-approves-antiviral-favilavir-to-treat-coronavirus\/5291581953892\/. p. 1."},{"key":"cit0110","unstructured":"Fujifilm Toyama Chemical. Fujifilm\u2019s antiviral becomes first approved drug to treat Coronavirus in China - COVID-19. Hospimedica Int; 2020 [cited 2020 Apr 12]. Available from: https:\/\/www.hospimedica.com\/covid-19\/articles\/294781247\/fujifilms-antiviral-becomes-first-approved-drug-to-treat-coronavirus-in-china.html"},{"key":"cit0111","unstructured":"PTI. \u201cFavilavir\u201d: first approved drug to possibly treat coronavirus. Sci Times. 2020 [cited 2020 Apr 12]. Available from: https:\/\/www.sciencetimes.com\/articles\/25053\/20200317\/favilavir-first-approve-drug-treat-coronavirus.htm. p. 1."},{"key":"cit0112","unstructured":"Glenmark begins phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 patients in India. The Hindu. n.d. [cited 2020 Jun 16]. Available from: https:\/\/www.thehindu.com\/news\/national\/glenmark-begins-phase-3-clinical-trials-on-antiviral-drug-favipiravir-for-covid-19-patients-in-india\/article31563198.ece"},{"key":"cit0113","unstructured":"Chaudhury DR. Russia enters final stage of clinical trial of drug to treat COVID patients. The Economic Times. 2020 [cited 2020 Jun 16]. Available from: https:\/\/economictimes.indiatimes.com\/news\/international\/business\/russia-enters-final-stage-of-clinical-trial-of-drug-to-treat-covid-patients\/articleshow\/75889651.cms?from=mdr"},{"key":"cit0114","unstructured":"Carlson R. Coronavirus breaking news. Coronavirus Today. 2020 [cited 2020 Jun 16]. Available from: https:\/\/www.coronavirustoday.com\/coronavirus-breaking-news\/#\/2020\/06\/01\/russia-approves-avifavir-covid-19-treatment. p. 1."},{"key":"cit0115","unstructured":"CytoDyn. Annual report pursuant to Section 13 or 15(d) of the securities exchange Act of 1934. United State Secur Exch Comm Washingt; 2019 [cited 2020 Apr 19]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1175680\/000119312519221300\/d40614d10k.htm"},{"key":"cit0116","unstructured":"PTI. CytoDyn files for breakthrough therapy designation with the FDA for the use of Leronlimab for the treatment of metastatic triple-negative breast cancer. Biospace; 2020 [cited 2020 Apr 19]. Available from: https:\/\/www.biospace.com\/article\/cytodyn-files-for-breakthrough-therapy-designation-with-the-fda-for-the-use-of-leronlimab-for-the-treatment-of-metastatic-triple-negative-breast-cancer\/. p. 1\u20133."},{"key":"cit0117","first-page":"1","author":"Tucker N","year":"2020","journal-title":"Target Oncol"},{"key":"cit0118","unstructured":"Vancouver. 54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far. Globe Newswire; 2020 [cited 2020 May 5]. Available from: https:\/\/www.cytodyn.com\/newsroom\/press-releases\/detail\/424\/cytodyn-reports-strong-results-from-eind-covid-19-patients. p. 1."},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1007\/s40278-020-75084-2"},{"key":"cit0120","unstructured":"McKee S. Positive early data from siltuximab COVID-19 trial. Pharma Times Online. 2020. p. 1."},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.01.20048561"},{"key":"cit0122","unstructured":"Update on Siltuximab clinical study: interim analysis data for Siltuximab-treated COVID-19 patients. Ergomed; 2020 [cited 2020 Jun 17]. Available from: https:\/\/www.ergomedplc.com\/update-on-siltuximab-clinical-study-interim-analysis-data-for-siltuximab-treated-covid-19-patients\/"},{"key":"cit0123","unstructured":"Watch C. Actemra (tocilizumab) injection. Cent Watch; 2017 [cited 2020 Apr 12]. Available from: https:\/\/www.centerwatch.com\/directories\/1067-fda-approved-drugs\/listing\/3072-actemra-tocilizumab-injection. p. 1."},{"key":"cit0124","unstructured":"Parsons L. FDA approves Roche\u2019s Actemra COVID-19 trial. PMLIVE. 2020;1. [cited 2020 Mar 30]. Available from: http:\/\/www.pmlive.com\/pharma_news\/fda_approves_roches_actemra_covid-19_trial_1329887"},{"key":"cit0125","unstructured":"Sanofi G. KEVZARA\u00ae (sarilumab). Sanofi US 2020; [cited 2020 Apr 12]. Available from: https:\/\/www.kevzara.com\/"},{"key":"cit0126","unstructured":"Blankenship K. With Kevzara in COVID-19 testing, Sanofi and Regeneron won\u2019t divvy up their rights. Fierce Pharma. 2020. p. 1."},{"key":"cit0127","unstructured":"Kolata G. Arthritis drug did not help seriously Ill COVID patients, early data shows. New York Times. 2020 [cited 2020 Jun 17]. Available from: https:\/\/www.nytimes.com\/2020\/04\/27\/health\/coronavirus-drug-sarilumab.html"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"cit0129","first-page":"1","author":"Lee HS","year":"2020","journal-title":"Korea Biomed Rev"},{"key":"cit0130","unstructured":"Metz C. How A.I. steered doctors toward a possible coronavirus treatment. New York Times. 2020.p. 1."},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"cit0132","first-page":"1","author":"Bender K","year":"2020","journal-title":"Infect Dis Today"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11140"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11135"},{"key":"cit0136","unstructured":"Sobi. Sobi\u2019s Anakinra & Emapalumab requested for use in targeted clinical study in Italy to address severe COVID-19 cases. Trial Site News. 2020.p. 1\u20132."},{"key":"cit0137","unstructured":"Kohli KK. Colchicine may reduce COVID-19 complications, hypothesize researchers. Med Dialogues; 2020 [cited 2020 May 5]. Available from: https:\/\/medicaldialogues.in\/medicine\/news\/colchicine-may-reduce-covid-19-complications-hypothesize-researchers-64204. p. 1."},{"key":"cit0138","unstructured":"Norton A. Could the ancient drug Colchicine help fight COVID-19? Med Heal News. 2020 [cited 2020 May 5]. Available from: https:\/\/www.medicinenet.com\/script\/main\/art.asp?articlekey=230649. p. 1."},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1093\/EHJCVP\/PVAA033"},{"key":"cit0140","unstructured":"Arnarson A. Side effects of melatonin: what are the risks? Healthline; 2018 [cited 2020 Jun 15]. Available from: https:\/\/www.healthline.com\/nutrition\/melatonin-side-effects. p. 1."},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161228122115"},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117583"},{"key":"cit0143","first-page":"1","author":"Balfour H","year":"2020","journal-title":"Eur Pharm Rev"},{"key":"cit0144","unstructured":"Synairgen. Phase II trial of SNG001 in coronavirus patients set to start. Technol Networks; 2020 [cited 2020 Apr 12]. Available from: https:\/\/www.technologynetworks.com\/drug-discovery\/news\/phase-ii-trial-of-sng001-in-covid-19-patients-set-to-start-332223. p. 1."},{"key":"cit0145","unstructured":"Wilkinson T. A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled. SNG001. Synairgen Res Ltd; 2020 [cited 2020 May 5]. Available from: https:\/\/www.hra.nhs.uk\/covid-19-research\/approved-covid-19-research\/281317\/. p. 1."},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01168-19"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036194"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.06.081968"},{"key":"cit0149","unstructured":"PTI. COVID 19: six Indian companies working on coronavirus vaccine. Live Mint News. 2020. p. 1."},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2005630"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5"},{"key":"cit0152","unstructured":"WHO. Draft landscape of COVID-19 candidate vaccines. World Heal Organ; 2020 [cited 2020 Jun 17]. Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"cit0153","unstructured":"BS Team. Covid-19: ICMR bats for Oxford vaccine, WHO lists 3 more as frontrunners. Bus Stand News. 2020 [cited 2020 Apr 20]. Available from: https:\/\/www.business-standard.com\/article\/current-affairs\/covid-19-icmr-bats-for-oxford-vaccine-who-lists-3-more-as-frontrunners-120041900954_1.html. p. 1."},{"key":"cit0154","unstructured":"Corum J, Zimmer C. Coronavirus vaccine tracker. The New York Times. 2020 [cited 2020 Jun 16]. Available from: https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html"},{"key":"cit0155","unstructured":"Varma K. China begins phase-II clinical trial of Covid-19 vaccine in Wuhan. Health News, ET HealthWorld. 2020 [cited 2020 Jun 16]. Available from: https:\/\/health.economictimes.indiatimes.com\/news\/industry\/china-begins-phase-ii-clinical-trial-of-covid-19-vaccine-in-wuhan\/75132720"},{"key":"cit0156","unstructured":"Vaccitech Limited. ChAdOx1-HBV Vaccine safety study - full text view. U S Natl Libr Med; 2020 [cited 2020 Apr 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04297917. p. 1."},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00440-20"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2004-145"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa106"},{"key":"cit0161","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa525"},{"key":"cit0162","first-page":"7:1157\u20131168","author":"Wu D","year":"2020","journal-title":"Natl Sci Rev"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01590-2"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26009"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108464"},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa392"},{"journal-title":"J Travel Med","year":"2020","author":"Wang W","key":"cit0167"},{"key":"cit0168","volume-title":"Learn. from SARS Prep. Next Dis. Outbreak","volume":"1","author":"Mark R","year":"2004","edition":"1"},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00344-20"},{"key":"cit0170","first-page":"e00297","volume":"5","author":"Alakwaa FM","year":"2020","journal-title":"Am Soc Microbiol"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.07.051"},{"key":"cit0172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190976"},{"key":"cit0173","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd0110"},{"key":"cit0174","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30222-8"},{"key":"cit0175","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30225-3"},{"key":"cit0176","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.01.001"},{"key":"cit0177","first-page":"0","volume":"2","author":"Luo W","year":"2020","journal-title":"J Med Virol"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2020.1810663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T08:44:19Z","timestamp":1667810659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2020.1810663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":178,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/14728214.2020.1810663"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2020.1810663","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"type":"print","value":"1472-8214"},{"type":"electronic","value":"1744-7623"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}